founders, Board of directors 

& Management

Founded by scientists who are driven to find treatments for rare neuromuscular diseases our research, drug programs and commercial efforts are all guided by science & the practice of evidence based translational development of our therapeutic strategies. 

Our goal is to develop the worlds first gene therapy to treat FSHD using novel patented CRISPRi technology.

There is currently no therapeutic treatment or cure for FSHD.

 

Peter L Jones PhD.

CSO, Founder, Board Director

Dr. Peter Jones is an Associate Professor of Pharmacology, the Mick Hitchcock, PhD, Endowed Chair of Medical Biochemistry at the University of Nevada, Reno School of Medicine

 

Peter L Jones PhD.

Dr. Peter Jones is an Associate Professor of Pharmacology, the Mick Hitchcock, PhD, Endowed Chair of Medical Biochemistry at the University of Nevada, Reno School of Medicine, and an affiliate scientist in the Sen. Paul D. Wellstone Cooperative Research Center for Muscular Dystrophy in Seattle. 

Learn More

 

 

Mick Hitchcock PhD.

Dr Hitchcock is a bio-pharmaceutical senior executive & researcher with 40 years of experience in the development of pharmaceuticals.  He spent 27 years with Gilead Sciences and helped to build it from the small, research-focused organization with 100 employees in 1993 with no products to the 5th largest pharmaceutical company (by market cap) 

Learn More

 

Mick Hitchcock PhD.

Non Exec Chair, Founder, Board Director

Dr. Hitchcock is a bio-pharmaceutical senior executive & researcher with 40 years of experience in the development of pharmaceuticals 

Dr. Peter Jones is an Associate Professor of Pharmacology, the Mick Hitchcock, PhD, Endowed Chair of Medical Biochemistry at the University of Nevada, Reno School of Medicine

Daniel Perez

Patient Liaison

Daniel Perez is one of the leading advocates and experts on living with facioscapulohumeral muscular dystrophy, FSHD molecular and genetics research & clinical aspects of FSHD

 

Daniel Paul Perez

Daniel Paul Perez is one of the leading advocates and experts on living with facioscapulohumeral muscular dystrophy (FSHD), FSHD molecular and genetics research and clinical aspects of FSHD.

 

Daniel established the FSHD Society in 1991 after meeting fellow FSHD patient and Society co-founder, Dr. Stephen Jacobsen.

Learn More

 

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Takako Jones PhD.

CSO, Founder, Board Director

Dr. T. Jones is an Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine 

 

Takako Iida Jones PhD.

Dr. T. Jones is an Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine.  She has a wide range of experience in the fields of developmental biology, cell biology, molecular genetics, and models of human disease.   

Learn More

 

 

Charis L Himeda PhD.

Dr. Himeda is an Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine. In the early stages of her career, she identified novel transcriptional regulators of muscle genes and helped design improved AAV regulatory cassettes which have been widely used in studies of muscle gene therapy. 

Learn More

 

Charis Himeda PhD.

CSO, Founder, Board Director

Dr. Himeda is an Associate Professor of Pharmacology at the University of Nevada, Reno School of Medicine

Pete Ratcliffe

Executive Chairman, President, Founder, Board Director

Pete has 23 years commercial, operations, management & advisory experience in global roles across Europe, US & Asia 

 

Pete Ratcliffe

Pete has 23 years commercial, operations, management & advisory experience in global strategic consultancy roles across Europe, US, Asia & Australia.

He is the founder & Chairman of Agincourt Advisory, a private market advisory firm specializing in diversified alternative assets, pursing opportunistic interests in Private Equity & Venture asset classes.

Learn More

 

 

Carly Baum

Carly is a Certified Public Accountant with over 10 years of industry experience. She spent 7 years in public accounting, and most recently has been an accounting consultant for start ups in Silicon Valley.

Learn More

 

Carly Baum

VP Finance 

Carly is a Certified Public Accountant with over 10 years of industry experience

 

Susan J.S. Phenix, PhD

 

Susan holds a PhD in Chemical Engineering from MIT and has over 19 years of industrial experience in pharmaceutical development at Pfizer and Genetics Institute/Wyeth BioPharma.  

 

Learn More

 

Susan J.S. Phenix PhD.

Scientific Advisor Pharmaceutical Development & CMC

Susan has over 19 years industrial experience in pharmaceutical development at Pfizer and Genetics Institute/Wyeth BioPharma